Parkman Healthcare Partners LLC Has $7.50 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Parkman Healthcare Partners LLC increased its stake in BioCryst Pharmaceuticals by 361.3%, now owning over 1 million shares valued at approximately $7.5 million.
• BioCryst Pharmaceuticals reported a quarterly earnings per share (EPS) of $0.15, significantly beating analyst expectations of $0.03, alongside a revenue increase of 49.5% year-over-year.
• Wall Street analysts have provided mostly positive ratings for BioCryst Pharmaceuticals, with an average price target of $16.70 and multiple firms upgrading their ratings to "buy" or "strong-buy."

Parkman Healthcare Partners LLC grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 361.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,000,562 shares of the biotechnology company's stock after buying an additional 783,681 shares during the quarter. Parkman Healthcare Partners LLC owned 0.48% of BioCryst Pharmaceuticals worth $7,504,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $33,000. GAMMA Investing LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,449 shares during the last quarter. New Age Alpha Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $62,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $79,000. Institutional investors and hedge funds own 85.88% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on BCRX shares. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Bank of America upped their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Wedbush upped their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday, June 30th. Finally, Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.70.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares of the company's stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.11 on Tuesday, reaching $8.08. 2,136,031 shares of the stock were exchanged, compared to its average volume of 2,192,808. The stock has a market cap of $1.70 billion, a PE ratio of -44.89, a P/E/G ratio of 1.86 and a beta of 1.13. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The stock has a 50 day moving average price of $8.49 and a 200 day moving average price of $8.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The business's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.06) earnings per share. On average, research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.